Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Patients with transitional cell cancer of the bladder, urethra, ureter, or renal pelvis
Patients who have archival tumor tissue available for FGFR3 mutational status screening
Patients with progressive disease
Patients with measurable disease by RECIST
Patients previously treated with at least 1 but not more than 3 systemic cytotoxic regimens with at least one of these regimens including at least one of the following: cisplatin, carboplatin, gemcitabine or taxane administered in the perioperative or advanced setting
Age ≥ 18 years
WHO Performance Status ≤ 2
Patients willing and able to take oral medication, follow scheduled visits, treatment plan and laboratory tests
Patients with signed and witnessed informed consent form
Patients with adequate organ function
You may not be if
Patients with brain cancer
Patients with other cancers except for certain skin, cervical \& prostate cancers
Patients who have not recovered from previous cancer treatment
Patients who have severe and/or uncontrolled medical conditions which could affect participation in the study
Clareo Health | Phase II Study of TKI258 in Advanced Urothelial Carcinoma
